PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer.
about
Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancerInteractions between tumor cells and microenvironment in breast cancer: a new opportunity for targeted therapyDissecting the Heterogeneity of Circulating Tumor Cells in Metastatic Breast Cancer: Going Far Beyond the Needle in the HaystackEndocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancersSingle cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell linesHormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profilingSingle cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.Expression microdissection adapted to commercial laser dissection instruments.Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial.PI3K pathway activation results in low efficacy of both trastuzumab and lapatinibCirculating tumor cells in breast cancer.Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis.Genetically engineered mouse models of PI3K signaling in breast cancer.The AURORA initiative for metastatic breast cancer.Discordance rate of HER2 status in primary gastric carcinomas and synchronous lymph node metastases: a multicenter retrospective analysisTargeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers.Concordance of genomic alterations between primary and recurrent breast cancer.Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.An emerging toolkit for targeted cancer therapies.Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies.Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.Differing von hippel lindau genotype in paired primary and metastatic tumors in patients with clear cell renal cell carcinoma.Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy.In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.PI3K expression and PIK3CA mutations are related to colorectal cancer metastases.The isolation and characterization of CTC subsets related to breast cancer dormancyKRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancerPIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients.Detection of tumor PIK3CA status in metastatic breast cancer using peripheral bloodRemarkable similarities of chromosomal rearrangements between primary human breast cancers and matched distant metastases as revealed by whole-genome sequencingTargeting tumor metastases: Drug delivery mechanisms and technologies.Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.The potential for liquid biopsies in the precision medical treatment of breast cancer.Phase II trial of temsirolimus in patients with metastatic breast cancer.Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumabTargeting the PI3K/Akt/mTOR pathway for breast cancer therapyThe favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer.The Conundrum of Genetic "Drivers" in Benign Conditions.Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity
P2860
Q26862550-D3FD224A-A48C-4CA5-A175-587D640FFB95Q27012888-8EA6095B-64FC-4DF2-957E-647EE9064DCCQ28067549-EC285EA9-5326-421C-AA05-1E574D329116Q28081872-5188F20E-3890-4063-ADD8-10847D88B41DQ28483475-53D839BD-9793-4D18-BE91-EC65A228EDA3Q33656801-E2AE5F87-7CB1-4B2D-B986-711FC6725C87Q33716499-21B68DC5-A338-4BBD-BE71-7203320E6317Q33806957-3F1E75B6-875F-40F3-A1C2-3E79419770E7Q33848897-D45565B9-CA12-4638-98C7-6DEAAA13D9A3Q33877385-6ADA5540-B282-40FB-A6BD-E1778C4020A9Q33933626-56770F24-4766-46AF-8782-04D5A1CEC466Q34077349-07E20748-65AD-42A5-939E-D9C03467ED1DQ34112879-0229F8B6-F68B-4640-9136-733237BAB809Q34332175-3C45BEF5-11DA-4025-A32D-798CA294C476Q34499602-01987C83-7FCE-4BC1-88BD-49F83207833EQ34834419-BC6C979C-5A7E-4188-B179-0E42B6F037C0Q35092806-08F80A47-E5AB-4EF9-9F6D-6AFB3CEBF858Q35142440-D3EA221B-2293-41F7-8749-9315A9DBF98AQ35558909-3E011396-F193-4D64-92C1-AEA0F634858EQ35694357-5735D509-31BB-40D6-A56F-3CD87F7CF873Q35828697-3AA49886-2253-4BF9-8458-B8A2CFBE7769Q35833567-27070448-8ED8-45EF-8F4D-86B59F6C6A61Q35990536-44E23ABE-DCFF-4E25-BF95-E1A63FEE82E3Q36059989-2245BF33-4295-47B5-AE74-AA769D28DCBFQ36109108-6C52442F-9F4C-4956-BDA9-856422445A7CQ36121260-EB4BBF9B-09CA-40AC-835E-E863A7EB053DQ36343283-5183B47C-837B-4FF4-8307-29478CAD7E25Q36362489-AA4A60A9-91CA-4C95-93C3-4CAD89FF3B8FQ36371231-9C1A510A-4716-4C68-9137-B272F0B57DF5Q36497457-518B39C9-CA0E-4DBE-9BCB-CC74379C5A79Q36545690-E2F1833E-ECF3-4495-B2B8-7F8C0F4F3ADCQ36557855-A0BD3474-2D07-4EFD-A3D6-33ED4E8CA047Q36804506-55AAACBA-8ACC-4168-BF00-E5A0C19E2E94Q36849660-A09D175F-141E-4FC3-AFFE-2DF0C34FCD02Q36856121-D5158DB2-A940-48B9-B6B4-BA7957B20754Q36857506-83980108-3884-48A0-BE7E-FACC74475B9CQ37047669-64F0E675-DAFA-4782-90EA-255F9332FB7BQ37183710-1B9C2A76-871E-4128-884E-4906C5B0E9D5Q37245787-1715978F-307D-40E9-831D-38F5D711753FQ37661161-62BB121F-3E36-438D-9BB5-ED38AF9109F2
P2860
PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
PIK3CA mutations may be discor ...... atic disease in breast cancer.
@ast
PIK3CA mutations may be discor ...... atic disease in breast cancer.
@en
type
label
PIK3CA mutations may be discor ...... atic disease in breast cancer.
@ast
PIK3CA mutations may be discor ...... atic disease in breast cancer.
@en
prefLabel
PIK3CA mutations may be discor ...... atic disease in breast cancer.
@ast
PIK3CA mutations may be discor ...... atic disease in breast cancer.
@en
P2093
P1476
PIK3CA mutations may be discor ...... atic disease in breast cancer.
@en
P2093
Humphrey Gardner
J Carl Barrett
Jeanette Dupont Jensen
Marianne Ewertz
Raj Bandaru
Weihua Liu
Wolfgang Hackl
P304
P356
10.1158/1078-0432.CCR-10-1133
P407
P577
2010-10-12T00:00:00Z